Pegasys Catching Up To PEG-Intron; Schering Admits “Complacency”
Executive Summary
Schering-Plough plans to focus more directly on maintaining market share in the pegylated interferon market after losing about one-third of its share to Roche, Global Pharmaceuticals President Carrie Cox told a July 23 conference call
You may also be interested in...
Roche, Schering Look To Grow Hepatitis Market; Pegasys Share Surges
Roche and Schering-Plough are attempting to drive sales of their hepatitis products by growing the market while increasing share
Roche, Schering Look To Grow Hepatitis Market; Pegasys Share Surges
Roche and Schering-Plough are attempting to drive sales of their hepatitis products by growing the market while increasing share
Schering Sales Force Recruitment Is 80% Complete; Morale Remains High
Recruitment for Schering-Plough's sales force expansion is 80% complete, Global Pharmaceutical President Carrie Cox told investors during a year-end conference call Jan. 26